Table 1.
Baseline characteristics and treatment among Nordic BRCA2 carriers according to country.
| Denmark | Iceland | Norway | Sweden | Total | |
|---|---|---|---|---|---|
| Number of invasive cases | 335 | 187 | 24 | 62 | 608 |
| Year at dx, median [range] | 2005 [1977–2018] | 1994 [1980–2012] | 2006 [1994–2012] | 2002 [1975–2016] | 2001 [1975–2018] |
| Exit year, final check of life status | 2019 | 2017 | 2014 | 1991–2019 | 1991–2019 |
| Years of follow-up, median [range] | 10.1 [1–37] | 11.2 [1–38] | 6.3 [2–20] | 8.3 [1–37] | 9.8 [1–38] |
| Age at dx, median [range] | 45 [24–91] | 48 [29–82] | 52 [30–74] | 46 [27–86] | 46 [24–91] |
| Number of deaths | 72 (21%) | 116 (62%) | 3 (13%) | 25 (40%) | 216 (36%) |
| BC deaths | 45 | 78 | – | 19 | 142 |
| Unknown cause | 1 | 0 | 3 | 0 | 4 |
| Timing of genetic testing | 335 | 187 | 24 | 60 | 606 |
| Before or at dx | 62 (18%) | 136 (73%) | 24 (100%) | 9 (15%) | 231 (38%) |
| Within 2 y after dx | 127 (38%) | 34 (18%) | 0 (0%) | 26 (43%) | 187 (31%) |
| >2 y after dx | 146 (44%) | 17 (9%) | 0 (0%) | 25 (42%) | 188 (31%) |
| Unknown | 0 | 0 | 0 | 2 | 2 |
| Morphology | |||||
| Ductal | 287 (87%) | 160 (86%) | – | 48 (92%) | 495 (87%) |
| Lobular | 24 (7%) | 19 (10%) | – | 4 (8%) | 47 (8%) |
| Other | 18 (5%) | 8 (4%) | – | 0 | 26 (5%) |
| Unknown | 6 | 0 | 62 | 10 | 78 |
| Size in mm, median [range] | 19 [1–120] | 20 [1–110] | 10 [0–51] | 20 [4–51] | 20 [0–120] |
| Unknown | 5 | 14 | 1 | 1 | 21 |
| Lymph node positive | 173 (53%) | 94 (52%) | 5 (25%) | 32 (52%) | 304 (52%) |
| Unknown | 8 | 6 | 4 | 1 | 19 |
| Grade 1 | 39 (13%) | 20 (11%) | 3 (14%) | 2 (5%) | 64 (11%) |
| 2 | 138 (44%) | 85 (47%) | 12 (57%) | 13 (33%) | 248 (45%) |
| 3 | 135 (43%) | 76 (42%) | 6 (29%) | 25 (62%) | 242 (44%) |
| Unknown | 23 | 6 | 3 | 22 | 54 |
| Oestrogen-receptor positive | 253 (79%) | 136 (74%) | 15 (75%) | 43 (78%) | 447 (77%) |
| Unknown | 15 | 4 | 4 | 7 | 30 |
| Her2 positive | 20 (7%) | 4 (10%) | – | 3 (10%) | 27 (8%) |
| Unknown | 48 | 146 | 24 | 32 | 250 |
| Bilateral oophorectomy | 254 (76%) | 48 (26%) | 20 (83%) | 36 (58%) | 358 (59%) |
| Before BC dx | 16 (6%) | 8 (17%) | 14 (70%) | 1 (3%) | 39 (11%) |
| ≤2 years after dx | 122 (48%) | 13 (27%) | 5 (25%) | 16 (44%) | 156 (44%) |
| >2 years after dx | 116 (46%) | 27 (56%) | 1 (5%) | 19 (53%) | 163 (45%) |
| Surgery at diagnosis | |||||
| Lumpectomy | 143 (44%) | 48 (26%) | 6 (29%) | 16 (26%) | 213 (36%) |
| Mastectomy | 185 (56%) | 138 (74%) | 15 (71%) | 46 (74%) | 384 (64%) |
| Unknown | 7 | 1 | 3 | 0 | 11 |
| Adjuvant chemotherapy | |||||
| None | 88 (30%) | 82 (45%) | – | 31 (50%) | 201 (37%) |
| Any | 207 (70 %) | 101 (55%) | – | 31 (50%) | 339 (63%) |
| Anthracycline | 163 | 51 | – | 24 | 238 |
| Non-anthracycline | 41 | 50 | – | 7 | 98 |
| Unknown type | 3 | 0 | – | 0 | 3 |
| Unknown | 40 | 4 | 24 | 0 | 68 |
| Radiation | |||||
| None | 71 (26%) | 86 (47%) | – | 23 (37%) | 180 (35%) |
| Any | 204 (74%) | 98 (53%) | – | 39 (63%) | 341 (65%) |
| Unknown | 60 | 3 | 24 | 0 | 87 |
| Endocrine therapy | |||||
| None | 123 (44%) | 94 (51%) | – | 22 (36%) | 239 (45%) |
| Any | 159 (56%) | 89 (49%) | – | 39 (64%) | 287 (55%) |
| Tamoxifen | 35 | 74 | – | 21 | 130 |
| Other type | 12 | 14 | – | 18 | 44 |
| Unknown type | 112 | 1 | – | 0 | 113 |
| Unknown | 53 | 4 | 24 | 1 | 82 |
| Anti-HER2 therapy | |||||
| None | 322 (96%) | 184 (99%) | – | 60 (97%) | 566 (97%) |
| Any | 13 (4%) | 1 (1%) | – | 2 (3%) | 16 (3%) |
| Unknown | 0 | 2 | 24 | 0 | 26 |